The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 20, 2009
Filed:
Jun. 02, 2005
Kevin Joseph Moriarty, Norristown, PA (US);
Yvonne Shimshock, Hillsborough, NJ (US);
Gulzar Ahmed, Yardley, PA (US);
Junjun Wu, Malden, MA (US);
James Wen, Dayton, NJ (US);
Wei LI, Acton, MA (US);
Shawn David Erickson, Leonia, NJ (US);
Jeffrey John Letourneau, East Windsor, NJ (US);
Edward Mcdonald, Banstead, GB;
Katerina Leftheris, Skillman, NJ (US);
Stephen T. Wrobleski, Whitehouse Station, NJ (US);
Zahid Hussain, Monmouth Junction, NJ (US);
Ian Henderson, Hopewell, NJ (US);
Axel Metzger, East Windsor, NJ (US);
John J. Baldwin, Gwynedd Valley, PA (US);
Alaric J. Dyckman, Lawrenceville, NJ (US);
Kevin Joseph Moriarty, Norristown, PA (US);
Yvonne Shimshock, Hillsborough, NJ (US);
Gulzar Ahmed, Yardley, PA (US);
Junjun Wu, Malden, MA (US);
James Wen, Dayton, NJ (US);
Wei Li, Acton, MA (US);
Shawn David Erickson, Leonia, NJ (US);
Jeffrey John Letourneau, East Windsor, NJ (US);
Edward McDonald, Banstead, GB;
Katerina Leftheris, Skillman, NJ (US);
Stephen T. Wrobleski, Whitehouse Station, NJ (US);
Zahid Hussain, Monmouth Junction, NJ (US);
Ian Henderson, Hopewell, NJ (US);
Axel Metzger, East Windsor, NJ (US);
John J. Baldwin, Gwynedd Valley, PA (US);
Alaric J. Dyckman, Lawrenceville, NJ (US);
Pharmacopeia, Inc., Cranbury, NJ (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.